Nuclear Medicine Therapy

  ARE YOU SUFFERING FROM HCC? (We are recruiting subjects for a clinical trial in the use of GPC-3 based PET-CT scan in patients of Hepatocellular Carcinoma). Backgroung: Glypican-3 (GPC3) is an oncofetal glycoprotein attached to the cell membrane. The expression of GPC3 is seen in various tumors, most notably in hepatocellular carcinomas(HCCs). Since GPC3 is not expressed in normal adult human tissue. GPC3 is considered an attractive target for tumor-directed diagnostics and therapy. If you are more than 18 years of age and suffering from a suspected hepatocellular carcinoma you may be eligible for this trial. Read more at https://nuclearmedicinetherapy.in/blog/hepato-cellular-carcinoma-hcc-clinical-trial Original Source: https://nuclearmedicinetherapy.in

  Yttrium-90 or Y-90 is a commonly used isotope in the medical field specially in departments like nuclear medicine and radiation oncology for radiation therapy. This radioisotope is relied upon to provide a prescribed amount of radiation to a targeted area , such as a tumor. One of the most common uses of Y90 is during an internal radiation therapy called radioembolization. Radioembolization or  Transarterial Radioembolization  using Y-90 involves the use of glass/ resin spheres that are filled with the isotope and placed directly into the blood supply of the liver tumor through a minimally invasive procedure. These spheres get lodged within the tumor itself. The doctors then block off the blood vessels to prevent blood flow (embolization). These Y-90 labelled spheres then get to work by radiating and destroying the tumor. Commonly, Y-90 labelled spheres are used for the treatment of liver tumors, primary hepatocellular carcinoma (HCC) and unresectable primary colore...

  The incidence of Hepatocellular Carcinoma or HCC has been increasing over the past several years and several studies have projected that the incidence of HCC will continue to rise in the coming years. Transarterial Chemoembolisation or TACE has been the initial treatment modality for HCC and has a huge body of evidence from several studies and clinical trials. Therefore, for long TACE has been a preferred treatment algorithm for unresectable HCC. However, as the experience of  Transarterial Radioembolisation or TARE  has evolved, it is playing an increasingly important role in the treatment of unrespectable HCC. Studies and trials have shown that TARE has many potential advantages over TACE and there is now substantial evidence to favor TARE over TACE. The many potential advantages of TARE when compared with TACE are as below: · Several studies have shown a statistically significant overall survival advantage with TARE as compared to TACE. · TARE has better health-relat...